Introduction: Although international clinical practice guidelines recognize a continued role
for menopausal hormone therapy (HT), particularly for symptomatic women< 60 years of age …

PET imaging of proteins in the human brain with high affinity radiolabelled molecules has a
history stretching back over 30 years. During this period the portfolio of protein targets that …

Substance P (SP) is an 11-amino acid neuropeptide of the tachykinin family that
preferentially activates the neurokinin-1 receptor (NK1R). First isolated 85 years ago and …

Vasomotor symptoms (VMS) are characteristic of menopause experienced by over 75% of
postmenopausal women with significant health and socioeconomic implications. Although …

Menopause is associated with significant symptomatic burden, with approximately two-thirds
of postmenopausal women suffering from vasomotor symptoms, hot flushes, and night …

Introduction Menopausal vasomotor symptoms (VMS) are experienced by most women and
are often debilitating and can last for years. While hormone replacement therapy is effective …

The discovery and development of central nervous system (CNS) drugs is an extremely
challenging process requiring large resources, timelines, and associated costs. The high …

Addiction is a chronic disorder in which consumption of a substance or a habitual behavior
becomes compulsive and often recurrent, despite adverse consequences. Substance p (SP) …

Stress-related substance use is a major challenge for treating substance use disorders. This
selective review focuses on emerging pharmacotherapies with potential for reducing stress …

The neurokinins are a class of peptide signaling molecules that mediate a range of central
and peripheral functions including pain processing, gastrointestinal function, stress …